Caris Life Sciences, backed by Sixth Street Partners, valued at $7.7 billion on Nasdaq.

From Investing.com: 2025-06-18 14:06:00

Caris Life Sciences, a precision medicine company backed by Sixth Street Partners, debuted on the Nasdaq with a valuation of $7.7 billion. The strong initial public offering performance reflects investor confidence in the company’s innovative approach to personalized cancer treatment. The IPO raised $1.4 billion, making it one of the largest healthcare offerings this year.



Read more at Investing.com: Sixth Street-backed Caris Life valued at $7.7 billion in strong Nasdaq debut